On October 30, 2017 Pfenex Inc. (NYSE MKT: PFNX) reported today that its third quarter 2017 financial results will be released on Thursday, November 9, 2017, after the market close (Press release, Pfenex, OCT 30, 2017, View Source2017-10-30-Pfenex-to-Report-Third-Quarter-2017-Results-and-Provide-Business-Update-on-Thursday-November-9-2017" target="_blank" title="View Source2017-10-30-Pfenex-to-Report-Third-Quarter-2017-Results-and-Provide-Business-Update-on-Thursday-November-9-2017" rel="nofollow">View Source [SID1234521317]). At 4:30 pm Eastern Time, Pfenex management will host a conference call to discuss the financial results and provide a business update. A press release outlining the financial results and business update will be publicly distributed prior to the call.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Please call 1-866-376-8058 (US) or 1-412-317-6011 (international) and reference Pfenex to access the call. A replay of the conference call will be available approximately one hour after the call until November 16, 2017. To access the teleconference replay please call 1-877-344-7529 (US) or 1-412-317-0088 (international) and enter the passcode 10113809. The conference call will also be available as a webcast. To access the webcast link please log on to www.pfenex.com.
Pfenex investors and others should note that we announce material information to the public about the Company through a variety of means, including our website (View Source), our investor relations website (View Source), press releases, SEC filings, public conference calls, corporate Twitter account (View Source), Facebook page (View Source), and LinkedIn page (View Source) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD. We encourage our investors and others to monitor and review the information we make public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.